OJOG  Vol.2 No.1 , March 2012
Cervical cancer screening: hTERC gene amplification detection by FISH in comparison with conventional methods
Aim: To assess the clinical significance of hTERC amplification for cervical cancer screening detected by fluorescence in situ hybridization (FISH) and compare it with that of current screening methods within the same group. Methods: A total of one hundred and nine women were recruited in this study. All of them had liquid-based thin-prep cytologic test (TCT), human papillomavirus (HPV) DNA testing and hTERC gene amplification analysis using interphase two-color FISH. In addition, colposcopically directed biopsy and/or cone biopsy were conducted for definite histopathologic diagnosis for each case. The optimal threashold of hTERC gene amplification by fluorescence in situ hybridization (FISH) were assecced by receiver operating characteristic (ROC) curve. The results of hTERC gene amplification analysis were compared with the cytological analysis, HPV DNA testing and those of subsequent biopsies. Results: Among the 109 patients, 18 were benign lesion, 17 were LSIL, 66 were HSIL and 8 were invasive carcinoma of cervix (ICC). Of them, hTERC-positive cases were found in 0.0% (0/18) of normal specimens, 11.8% (2/17) of LSIL, 72.7% (48/66) of HSIL and 100.0% (8/8) of ICC, respectively. The positive rate of hTERC gene amplification was significantly higher in HSIL and ICC compared with normal and LSIL (all P < 0.01).The optimal cut-off point of percentages of cells with hTERC amplification was determined as 5.5%. Using this threshold the hTERC test reached a much higher specificity(94.3%, 33/35) and a relatively lower sensitivity(77.0%, 57/74) to distinguish benign lesion and LSIL from HSIL and ICC in comparison with HR-HPV test (51.4%; 91.9%) and TCT (74.3%; 81.1%). Area Under the Curve revealed that hTERC amplification test performed more accurately (area under the curve = 0.857) compared to HPV test (area under the curve = 0.717) and cytology(area under the curve = 0.777) to discriminate HSIL or higher from LSIL or lower. This study also found a significant positive correlation between positive hTERC gain and HR-HPV infection, abnormal cytological or histopathologic lesions (all P < 0.01) in patients with cervical diseases. Conclusion: hTERC amplification testing may be a promising adjunct to screen women for cervical precancer or cancer with high specificity and accuracy.

Cite this paper
Guo, Q. , Sui, L. and Feng, Y. (2012) Cervical cancer screening: hTERC gene amplification detection by FISH in comparison with conventional methods. Open Journal of Obstetrics and Gynecology, 2, 11-17. doi: 10.4236/ojog.2012.21003.
[1]   GLOBOCAN 2008 v1.2, Cancer incidence and mortality worldwide: IARC CancerBase No. 10. http://globocan.iarc.fr.

[2]   Lehtinen, M., Pawlita, M., Zumbach, K., et al. (2003) Evaluation of antibody response to human papillomavirus early proteins in women in whom cervical cancer developed 1 to 20 years later. American Journal of Obstetrics & Gynecology, 188, 49-55. doi:10.1067/mob.2003.98

[3]   Nanda, K., McCrory, D.C., Myers, E.R., et al. (2000) Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: A systematic review. Annals of Internal Medicine, 132, 810-819. doi:10.1111/j.1526-0976.2001.51012-12.pp.x

[4]   Siebers, A.G., Klinkhamer, P.J., Grefte, J.M., et al. (2009) Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: A randomized controlled tral. Journal of the American Medical Association, 302, 1757-1764. doi:10.1001/jama.2009.1569

[5]   Ronco, G., Cuzick, J., Pierotti, P., et al. (2007) Accuracy of liquid based versus conventional cytology: Overall results of new technologies for cervical cancer screening: Randomised controlled trial. British Medical Journal, 335, 28. doi:10.1136/bmj.39196.740995.BE

[6]   An, H.J., Kim, K.R., Kim, I.S., et al. (2005) Prevalence of human papillomavirus DNA in various histological subtypes of cevical adenocarcinoma: A population-based study. Modern Pathology, 18, 528-534. doi:10.1038/modpathol. 3800316

[7]   Kitchener, H.C., Almonte, M., Gilham, C. et al. (2009) ARTISTIC: A randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technology Assessment, 13, 1-150, doi:10.3310/hta13510

[8]   Grce, M. and Davies, P. (2008) Human papillomavirus testing for primary cervical cancer screening. Expert Review of Molecular Diagnostics, 8, 599-605. doi:10.1016/S0140-6736(07)61480-9

[9]   Cuzick, J., Clavel, C., Petry, K.U., et al. (2006) Overview of the European and North American studies on HPV testing in primary cervical cancer screening. International Journal of Cancer, 119, 1095-1101. doi:10.1002/ijc.21955

[10]   Hopman, A.H., Theelen, W., Hommelberg, P.P., et al. (2006) Genomic integration of oncogenic HPV and gain of the human telomerase gene TERC at 3q26 are strongly associated events in the progression of uterine cervical dysplasia to invasive cancer. Journal of Pathology, 210, 412-419. doi:10.1002/path.2070

[11]   Zhao, J.Q., Glasspool, R.M., Hoare, S.F., et al. (2000) Activation of telomerase rna gene promoter activity by NF-Y, Sp1, and the retinoblastoma protein and repression by Sp3. Neoplasia, 2, 531-539. doi:10.1038/sj.neo.7900114

[12]   Kokalj-Vokac, N., Kodric, T., Erjavec-Skerget, A., Zagorac, A. and Takac, I. (2009) Screening of TERC gene amplification as an additional genetic diagnostic test in detection of cervical preneoplastic lesions. Cancer Genetics and Cytogenetics, 195, 19-22. doi:10.1016/j.cancergencyto.2009.01.005

[13]   Zheng, L., Liu, A.L., Qi, T., et al. (2010) Human telomerase RNA gene amplification detection increases the specificity of cervical intraepithelial neoplasia screening. International Journal of Gynecological Cancer, 20, 912-917. doi:10.1111/IGC.0b013e3181e5c424

[14]   Heselmeyer-Haddad, K., Janz, V., Castle, P.E., et al. (2003) Detection of genomic amplification of the human telomerase gene (TERC) in cytologic specimens as a genetic test for the diagnosis of cervical dysplasia. American Journal of Pathology, 163, 1405-1416. doi:10.1016/S0002-9440(10)63498-0

[15]   Andersson, S., Sowjanya, P., Wangsa, D., et al. (2009) Detection of genomic amplification of the human telomerase gene TERC, a potential marker for triage of women with HPV-positive, abnormal Pap smears. American Journal of Pathology, 175, 1831-1847. doi:10.2353/ajpath.2009.090122

[16]   Mahon, M.M., Cox, I.J., Dina, R., et al. (2004) (1)H magnetic resonance spectroscopy of preinvasive and invasive cervical cancer: In vivo-ex vivo profiles and effect of tumor load. Journal of Magnetic Resonance Imaging, 19, 356-364. doi:10.1002/jmri.20012

[17]   Tu, Z., Zhang, A., Wu, R., et al. (2009) Genomic amplification of the human telomerase RNA gene for differential diagnosis of cervical disorders. Cancer Genetics and Cytogenetics, 91, 10-16. doi:10.1016/j.cancergencyto.2009.01.004

[18]   Akobeng, A.K. (2007) Understanding diagnostic tests 3: Receiver operating characteristic curves. Acta Paediatrica, 96, 644-647. doi:10.1111/j.1651-2227.2006.00178.x

[19]   Olaharski, A.J., Sotelo, R., Solorza-Luna, G., et al. (2006) Tetraploidy and chromosomal instability are early events during cervical carcinogenesis. Carcinogenesis, 27, 337-343. doi:10.1093/carcin/bgi218

[20]   Caraway, N.P., Khanna, A., Dawlett, M., et al. (2008) Gain of the 3q26 region in cervicovaginal liquid-based pap preparations is associated with squamous intraepithelial lesions and squamous cell carcinoma. Gynecologic Oncology, 110, 37-42. doi:10.1016/j.ygyno.2008.01.040

[21]   Oikonomou, P., Mademtzis, I., Messinis, I., Tsezou, A. (2006) Quantitative determination of human telomerase reverse transcriptase messenger RNA expression in premalignant cervical lesions and correlation with human papillomavirus load. Human Pathology, 37, 135-142. doi:10.1016/j.humpath.2005.09.031

[22]   Sui, W., Ou, M., Dai, Y., et al. (2009) Gain of the human telomerase RNA gene TERC at 3q26 is strongly associated with cervical intraepithelial neoplasia and carcinoma. International Journal of Gynecological Cancer, 19, 1303-1306. doi:10.1111/IGC.0b013e3181b62ea5

[23]   Li, Y., Ye, F., Lu, W.G., Zeng, W.J., Wei, L.H. and Xie, X. (2010) Detection of human telomerase RNA gene in cervical cancer and precancerous lesions: Comparison with cytological and human papillomavirus DNA test findings. International Journal of Gynecological Cancer, 20, 631-637. doi:10.1111/IGC.0b013e3181c50c7e

[24]   Heselmeyer-Haddad, K., Sommerfeld, K., White, N.M., et al. (2005) Genomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancer. American Journal of Pathology, 166, 1229-1238. doi:10.1016/S0002-9440(10)62341-3

[25]   Yugawa, T. and Kiyono, T. (2009) Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: Novel functions of E6 and E7 oncoproteins. Reviews in Medical Virology, 19, 97-113. doi:10.1002/rmv.605

[26]   Takac, I., Arko, D., Kodric, T., et al. (2009) Human telomerase gene amplification and high-risk human papillomavirus infection in women with cervical intra-epithelial neoplasia. Journal of International Medical Research, 37, 1588-1595. doi:10.1111/IGC.0b013e3181e5c